Journal ArticleDOI
Cannabinoids in treatment-resistant epilepsy: A review.
TLDR
Open-label studies with 100mg/ml CBD have provided additional evidence of its efficacy along with an adequate safety profile in children and young adults with a spectrum of TREs and Phase 3 RCTs with Epidiolex support efficacy and adequate safety profiles for children with DS and LGS.About:
This article is published in Epilepsy & Behavior.The article was published on 2017-05-01. It has received 162 citations till now. The article focuses on the topics: Cannabis & Cannabidiol.read more
Citations
More filters
Journal ArticleDOI
Marijuana Use in Young Adults: What Do We Know?
Wenzinger Michael,Fears Fayola +1 more
TL;DR: No strong evidence supports marijuana as a beneficial treatment for any psychiatric indication, however there is evidence supporting the use of cannabidiol (CBD) in illnesses such as epilepsy.
Journal ArticleDOI
Genome-wide DNA methylation association study of recent and cumulative marijuana use in middle aged adults.
Drew R. Nannini,Yinan Zheng,Brian T. Joyce,Kyeezu Kim,Tao Gao,Jun Wang,David R. Jacobs,Pamela J. Schreiner,Kristine Yaffe,Philip Greenland,Donald M. Lloyd-Jones,Lifang Hou +11 more
TL;DR: This paper investigated the association between recent and cumulative marijuana use and DNA methylation levels and identified numerous methylation markers, pathways, and diseases associated with marijuana use in middle-aged adults.
Journal ArticleDOI
The Synthetic Cannabinoid WIN55,212-2 Can Disrupt the Golgi Apparatus Independent of Cannabinoid Receptor-1
TL;DR: The results show that WIN can disrupt the Golgi apparatus independent of CB1 in cultured cells, which could contribute to the unique physiologic effects that WIN exhibits in neuronal behavior, as well as its role as an antiproliferative and anti-inflammatory agent.
Medical Marijuana: A Hope For Resistant Epilepsy?
Arsalan Anwar,Sidra Saleem +1 more
TL;DR: In this article, the psychoactive parttetrahydrocannabinol (THC) targets CB1 and CB2receptors in the body and counteracts reactive oxygen species and the Cannabinoidiol (CBD) component is famous for itsmedicinal use that works without interacting with these receptors and is free of psychiatric side effects.
References
More filters
Journal ArticleDOI
Early Identification of Refractory Epilepsy
TL;DR: Patients who have many seizures before therapy or who have an inadequate response to initial treatment with antiepileptic drugs are likely to have refractory epilepsy.
Journal ArticleDOI
Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies.
Patrick Kwan,Alexis Arzimanoglou,Anne T. Berg,Martin J. Brodie,W. Allen Hauser,Gary W. Mathern,Solomon L. Moshé,Emilio Perucca,Samuel Wiebe,Jacqueline A. French +9 more
TL;DR: It is proposed as a testable hypothesis that drug resistant epilepsy is defined as failure of adequate trials of two tolerated, appropriately chosen and used antiepileptic drug schedules to achieve sustained seizure freedom.
Journal ArticleDOI
Adverse Health Effects of Marijuana Use
TL;DR: As marijuana use becomes legal in some states, the dominant public opinion is that marijuana is a harmless source of mood alteration, but enough information is available to cause concern.
Journal ArticleDOI
Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders.
Orrin Devinsky,Maria Roberta Cilio,Helen Cross,Javier Fernández-Ruiz,Jacqueline A. French,Charlotte L Hill,Russell Katz,Vincenzo Di Marzo,Didier Jutras-Aswad,William George Notcutt,José Martínez-Orgado,Philip Robson,Brian G. Rohrback,Elizabeth A. Thiele,Benjamin J. Whalley,Daniel Friedman +15 more
TL;DR: CBD bears investigation in epilepsy and other neuropsychiatric disorders, including anxiety, schizophrenia, addiction, and neonatal hypoxic‐ischemic encephalopathy, however, data from well‐powered double‐blind randomized, controlled studies on the efficacy of pure CBD for any disorder is lacking.
Journal ArticleDOI
Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial
Orrin Devinsky,Eric D. Marsh,Daniel Friedman,Elizabeth A. Thiele,Linda Laux,Joseph Sullivan,Ian Miller,Robert Flamini,Angus Wilfong,Francis Filloux,Matthew Wong,Nicole Tilton,Patricia L. Bruno,Judith Bluvstein,Julie Hedlund,Rebecca M. Kamens,Jane Maclean,Srishti Nangia,Nilika S. Singhal,Carey A Wilson,Anup D. Patel,Maria Roberta Cilio +21 more
TL;DR: The findings suggest that cannabidiol might reduce seizure frequency and might have an adequate safety profile in children and young adults with highly treatment-resistant epilepsy.
Related Papers (5)
Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial
Orrin Devinsky,Eric D. Marsh,Daniel Friedman,Elizabeth A. Thiele,Linda Laux,Joseph Sullivan,Ian Miller,Robert Flamini,Angus Wilfong,Francis Filloux,Matthew Wong,Nicole Tilton,Patricia L. Bruno,Judith Bluvstein,Julie Hedlund,Rebecca M. Kamens,Jane Maclean,Srishti Nangia,Nilika S. Singhal,Carey A Wilson,Anup D. Patel,Maria Roberta Cilio +21 more
Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial
Elizabeth A. Thiele,Eric D. Marsh,Jacqueline A French,Maria Mazurkiewicz-Bełdzińska,Selim R Benbadis,Charuta Joshi,Paul D Lyons,Adam Taylor,Claire Roberts,Kenneth W. Sommerville,Kenneth W. Sommerville,Boudewjin Gunning,Jacek Gawlowicz,Pawel Lisewski,Maria Mazurkiewicz Beldzinska,Krystyna Mitosek Szewczyk,Barbara Steinborn,Marta Zolnowska,Elaine Hughes,Ailsa McLellan,Selim R. Benbadis,Michael A. Ciliberto,Gary G. Clark,Dennis J. Dlugos,Francis Filloux,Robert Flamini,Jacqueline A. French,Michael Frost,Sheryl R. Haut,Siddarth Kapoor,Sudha Kilaru Kessler,Linda Laux,Paul D. Lyons,Eric D. Marsh,David Moore,Richard P. Morse,Venkatesh Nagaraddi,William E. Rosenfeld,Laurie E. Seltzer,Renée A. Shellhaas,Joseph Sullivan,Elizabeth A. Thiele,Liu Lin Thio,David Wang,Angus A. Wilfong +44 more